Drug Formulary Committee: Minutes of August 23, 2016 Public Meeting

Members in attendance
Al Heaton, RPh, Stuart Williams, J.D., Kathryn Lombardo, M.D., Kelly Ruby, Pharm.D., William Korchik, M.D., Michael Sprehe, M.D., James Phillips, M.D., Stacey Ness, Pharm.D

Members absent:
Margaret Artz, RPh, Ph.D., Monica Brands, R.Ph.

DHS staff present
Sara Drake, RPh., MPH, MBA, Dave Hoang, Pharm.D., MBA

Others in attendance
Nina Bandali, Pharm.D., Ariane Casey, Pharm.D.

Report of the Chair
No updates

Approval of the minutes
Minutes from the April 19, 2016 meetings was reviewed and approved

New Business
Stacey Ness was elected by a unanimous vote to be the next Chair of the Drug Formulary Committee

Class Review: Hepatitis C
The committee discussed two new hepatitis C direct acting antivirals (Zepatier and Epclusa) and recommended to the department by a unanimous vote that Zepatier and Epclusa remain on PA. The committee also recommended to the department that a ribavirin-free hepatitis C treatment option be available for those patients unable to tolerate ribavirin.

Discussion on Existing PA Criteria
The committee discussed existing PA criteria for antiepileptic drugs including Onfi, Aptiom, Vimpat, Fycompa and Banzel. The committee recommended to the department by a majority vote that Onfi, Aptiom, Vimpat, Fycompa and Banzel remain on PA with the following modifications to the criteria: (1) two-step therapy will be required if prescribed by neurologist; (2) three-step therapy will be required if prescribed by non-neurologist; (3) implement PDL strategy for Onfi and Banzel. One member opposed the recommendations above.

New Specialty Drugs for Continued PA
The committee discussed Kanuma (Alexion) and recommended to the department that Kanuma remain on PA by a unanimous vote.

The committee discussed Uptravi (Actelion) and recommended to the department by a unanimous vote that Uptravi remain on PA.
The committee discussed Strensiq (Alexion) and recommended to the department by a unanimous vote that Strensiq remain on PA.

The committee discussed Imlygic (Amgen) and recommended to the department by a unanimous vote that Imlygic remain on PA.

The committee discussed Yondelis (Janssen) and recommended to the department by a unanimous vote that Yondelis remain on PA.

The committee discussed Darzalex (Janssen) and recommended to the department by a unanimous vote that Darzalex remain on PA.

The committee discussed Empliciti (Bristol-Myers Squibb) and recommended to the department by a unanimous vote that Empliciti remain on PA.

The committee discussed Opdivo (Bristol-Myers Squibb) and recommended to the department by a unanimous vote that Opdivo remain on PA.

Specialty Product List Review
The committee reviewed specialty product list and recommended to the department by a unanimous vote that the following products be placed in the specialty product list:

- Cancidas (Merck)
- Ceprotin (Baxter)
- Egrifta (EMD Sorono)
- Elmiron (Janssen)
- Mirena (Bayer)
- Nimbex (AbbVie)
- Rapamune (Pfizer)
- Relistor (Salix)
- Syprine (Aton)
- Vivitrol (Alkermes)
- Xofigo (Bayer)
- Zyvox injection (Pfizer)

Adjournment
The meeting was adjourned at 10:00 pm Central Time.